AdvanSource Biomaterials Corporation (NYSE Alternext US: ASB), a
leading developer of advanced polymer materials for a broad range of
medical device applications, today announced that after assessment by
the International Organization for Standardization (ISO), the Company’s
Quality Management System has received ISO certification through SGS
United Kingdom Ltd. to ISO13485:2003 and 9001:2000 for the design and
manufacture of polymers for the medical device industry. ISO
certification is the preeminent worldwide standard for manufacturing and
quality control systems.
Commenting on today’s announcement, AdvanSource President and CEO
Michael Adams said, "The certifications we have just received are
recognized by all medical device developers and manufacturers as proof
of high product quality. By receiving ISO certification, AdvanSource has
reached a major milestone with a focus on continuous improvement as well
as expanding its ability to be chosen as a technology partner by both
existing and potential customers.”
About AdvanSource Biomaterials Corporation
AdvanSource Biomaterials Corporation manufactures advanced polymer
materials which provide critical characteristics in the design and
development of medical devices. The Company’s biomaterials are used in
devices that are designed for treating a broad range of anatomical sites
and disease states. AdvanSource’s business model leverages its
proprietary materials science technology and manufacturing expertise in
order to expand its product sales and royalty and license fee income.
The Company is conducting a clinical trial for regulatory approval at
two sites in Europe for its CardioPass™ synthetic coronary bypass graft.
More information about AdvanSource is available at its website: www.advbiomaterials.com
Forward-Looking Statements:
AdvanSource believes that this press release contains forward-looking
statements as that term is defined in the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements are subject to risks
and uncertainties. Such statements are based on management’s current
expectations and are subject to risks and uncertainties that could cause
results to differ materially from the forward-looking statements. For
further information on such risks and uncertainties, you are encouraged
to review AdvanSource’s filings with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for the fiscal year
ended March 31, 2008 and its Quarterly Reports on Form 10-Q for the
periods ended June 30, 2008 and September 30, 2008. AdvanSource assumes
no obligation to update any forward-looking statements as a result of
new information or future events or developments, except as required by
law.
AdvanSource Biomaterials
Eric Walters, 978-657-0075
Vice
President & CFO
info@advbiomaterials.com
or
VMW
Corporate & Investor Relations
Sylvia Dresner, 212-616-6161
Senior
Vice President
info@vmwcom.com
